The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK
Open Access
- 28 August 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 32 (20), 2525-2532
- https://doi.org/10.1093/eurheartj/ehr333
Abstract
The aim of this study was to determine the outcome benefits in those originally assigned atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial—8 years after closure of the lipid-lowering arm (LLA) of the trial (ASCOT-LLA) among the UK population. ASCOT-LLA was a factorially designed double-blind placebo-controlled trial of atorvastatin in 10 305 hypertensive patients enrolled into the ASCOT-Blood Pressure Lowering Arm (BPLA) of the trial and with total cholesterol concentrations, at baseline, of n= 520 and 460 in placebo and atorvastatin, respectively) remained significantly lower in those originally assigned atorvastatin (HR 0.86, CI 0.76–0.98, P= 0.02). CV deaths were fewer, but not significant (HR 0.89, CI 0.72–1.11, P= 0.32) and non-CV deaths were significantly lower (HR 0.85, CI 0.73–0.99, P= 0.03) in those formerly assigned atorvastatin attributed to a reduction in deaths due to infection and respiratory illness. Legacy effects of those originally assigned atorvastatin may contribute to long-term benefits on all-cause mortality. An explanation for long-term benefits on non-CV deaths has not been established.Keywords
This publication has 14 references indexed in Scilit:
- Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes TrialEuropean Heart Journal, 2011
- Statins in community acquired pneumonia: Evidence from experimental and clinical studiesRespiratory Medicine, 2010
- Statins for the Prevention and Treatment of InfectionsArchives of Internal Medicine, 2009
- The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closureEuropean Heart Journal, 2008
- Long-Term Follow-up of the West of Scotland Coronary Prevention StudyNew England Journal of Medicine, 2007
- Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA)The American Journal of Cardiology, 2005
- Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein CholesterolThe American Journal of Cardiology, 2005
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004
- Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-upThe Lancet, 2002
- Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled TrialJAMA, 2001